[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-gc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-gc":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,51,86,122,147,177,202,230,257,285,308,338,361,383,410,435,457,483,518,549,568,591,616,645,676],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100609678","phase-3-using-18f-fapi-pet-to-detect-metastatic-disease-in-patients-that-have-gastric-or-esophageal-cancer-100609678",false,"NCT07217704","Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET\u002FCT for the Detection of Metastatic Disease in Adults With Gastric or Esophageal Cancer","FAPI-GO","Inclusion Criteria:\n\n* Male and female adults ≥ 18 years.\n* Participants with confirmed gastric, esophageal or gastroesophageal malignancy undergoing staging evaluation for treatment planning.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Provided signed, written informed consent prior to any study-related procedures.\n* Participants are required to have a ceCT scan of chest, abdomen and pelvis as per standard clinical practice and practice guidelines either 21 days or less prior to entry or planned within 21 days of \\[¹⁸F\\]FAPI-74 administration.\n* For women who are not postmenopausal (two years of amenorrhea) or surgically sterile (absence of ovaries and\u002For uterus): agreement to use medically accepted, highly effective methods of contraception (e.g., hormonal implants, combined oral contraceptives, vasectomized partner, during the trial intervention period.\n\nExclusion Criteria:\n\n* Unequivocal evidence of metastases at the time of enrollment that would preclude surgery as a treatment option.\n* Known hypersensitivity to \\[¹⁸F\\]FAPI-74.\n* Administration of another investigational diagnostic or therapeutic product within 30 days prior to \\[¹⁸F\\]FAPI-74 administration.\n* Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of \\[¹⁸F\\]FAPI-74 administration.\n* Previous cancer (except basal cell carcinoma of the skin or in situ carcinoma of the cervix\u002Futerus (participants treated with curative intent and disease free for more than 5 years are permitted).\n* Hepatic function: T. bili \\>1.5X ULN or alk phos, ALT, or AST \\>5X ULN\n* Renal function: GFR \\\u003C 30 mL\u002Fmin\n* Pregnant or currently breast feeding (a negative pregnancy test is required in women of childbearing potential).\n* Inability to undergo the PET\u002FCT scanning procedure.\n* Inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Sarcoidosis\n* Treatment, including chemotherapy, radiation, immunotherapy or surgery for curative intent of Gastroesophageal cancers","ALL","18 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \\[¹⁸F\\]FAPI-74 PET\u002FCT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \\[¹⁸F\\]FAPI-74 PET\u002FCT screening. SOC procedures and interventions will be captured during 3 months +\u002F-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \\[¹⁸F\\]FAPI-74 PET\u002FCT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \\[¹⁸F\\]FAPI-74 PET\u002FCT.",[28,29,30],"Esophageal Cancer","Gastric Cancer (GC)","Gastroesophageal Junction",[32,33,34,35,36,37],"FAP","Fibroblast Activation Protein","Fibroblast Activation Protein Inhibitor","FAPI","gastroesophageal cancer","PET","RECRUITING","2026-06-26",{"date":41,"type":42},"2026-06-30","ACTUAL",{"date":44,"type":42},"2025-11-14",{"date":46,"type":22},"2027-08-30",{"name":48,"class":49},"SOFIE","INDUSTRY",15,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100642818","phase-1-the-0504-in-patients-with-solid-tumors-100642818","NCT07646106","THE-0504 in Patients With Solid Tumors","NANOFER-THE-0504: A Trial to Assess the Safety and Tolerability of an Investigational Drug THE-0504 for Patients With Solid Tumors","Inclusion Criteria:\n\nPatients will be enrolled in the study if they meet all the following criteria:\n\n1. written informed consent obtained;\n2. both gender adult (≥ 18 years) patients;\n3. diagnosis of solid tumor. Preferably, but non-limited, tumor types are the following: Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Pancreas Adenocarcinoma (PaAdCa), Gastric Cancer (GC) and Triple Negative Breast Cancer (TNBrCa);\n4. measurable metastatic disease or locally advanced unresectable tumors;\n5. have exhausted all EMA-approved treatment options;\n6. ECOG Performance Status graded as 0 or 1;\n7. patients able to understand the full nature and the purpose of the trial, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire trial (ability to attend all the planned trial visits according to the time limits included) based on Investigator's judgement;\n8. adequate liver function as assessed by following laboratory tests to be conducted within 28 days before the first dose of study treatment:\n\n   * Total bilirubin ≤ 1.5 × ULN (or ≤ 3 X ULN for patients with documented Gilbert-Meulengracht Syndrome, or for patients with hyperbilirubinemia considered due to liver metastasis).\n   * Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor);\n9. adequate kidney function as assessed by following laboratory test to be conducted within 28 days before the first dose of study treatment:\n\n   • Estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin per 1.73 m2 according to the CKD-EPI formula.\n10. adequate bone marrow function as defined as:\n\n    * Hgb ≥ 9 g\u002FdL\n    * ANC ≥1.5x109\u002FL\n    * PLT≥100.0 x109\u002FL\n11. Female patients of childbearing potential and male patients who are sexually active with women of childbearing potential will have to mandatorily use an appropriate method of contraception, according to the definition of Note 3 of ICH M3 Guideline, for the entire duration of the trial and for a minimum of 12 months after last administration of the IMP.\n\nExclusion Criteria:\n\nPatients will not be enrolled if they meet any of the following criteria:\n\n1. pregnant (as determined by a blood pregnancy test at the screening visit) or lactating women;\n2. male patients who are willing to father children during the trial or in the 12 months after the end of IMP administration;\n3. additional malignancy in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy;\n4. have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2 toxicities may be allowed to enrol after agreement between the Investigator and Sponsor;\n5. ECOG Performance Status \\> 2;\n6. had not tolerated previously administered Top1 inhibitor treatments;\n7. known active CNS metastatic disease (patients with CNS metastases that are treated with radiotherapy and are stable for at least 28 days before study treatment start could be considered eligible);\n8. serious concurrent illness;\n9. Hgb \\\u003C 9 g\u002FdL;\n10. Transfusion dependent anemia with transfusion dependency of ≥3 months;\n11. Clinically significant iron metabolism disorders (e.g., sickle cell anemia) or use of iron chelators treatments;\n12. Iron overload, hereditary hemochromatosis and similar;\n13. Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment;\n14. Prolonged QTc interval;\n15. Multiple Sclerosis (MS) or other demyelinating disease, Eaton-Lambert syndrome, history of haemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease;\n16. Non-healing wound(s), except for ulcerative lesions caused by the underlying neoplasm;\n17. History of severe allergic or anaphylactic reactions to previous protein-based therapy;\n18. Currently receiving anticoagulation therapy with warfarin;\n19. Known history of HIV infection, unless all the following are applicable:\n\n    * receiving an approved, stable, effective combination antiretroviral therapy regimen for ≥ 3 months prior to the planned first study intervention;\n    * CD4 T-cell count \\> 350 cells\u002FμL\n    * CD4 T-cell nadir (lowest historical count) \\> 350 cells\u002FμL, and • viral load confirmed as \\\u003C 50 copies\u002FmL.\n20. HBV infection, unless on stable anti-viral therapy for \\> 4 weeks prior to the planned first dose of study intervention and viral load confirmed as undetectable; and HCV infection, unless the participant has received curative treatment and viral load was confirmed as undetectable;\n21. Known autoimmune disease, uncontrolled diabetes, vitiligo, or stable thyroid disease;\n22. Patients on chronic (more than 10 days) administration of systemic, high-dose corticosteroids (≥4 mg Dexamethasone or equivalent), not amenable for reduction or suspension;\n23. Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations;\n24. History of drugs and\u002For alcohol abuse;\n25. Patients considered to be unsuitable to participate, in the Investigator's opinion, for any other reason (e.g. consequences of previous medical and\u002For surgical procedures or other medical or ethical reasons);\n26. Planned relocation during the study, which would make impossible to attend the scheduled visits and follow-ups;\n27. Concomitant participation in other clinical trials or participation in the evaluation of any investigational drugs\u002Fproducts up to 4 weeks before this trial (in any case, enrolment procedure should start only after the complete washout of the drugs\u002Fproducts under investigation\\*\\*); or previous participation in the same trial or planned to receive other investigational products during the study.",{"count":5,"type":22},[60],"PHASE1","Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.",[63,64,29,65,66],"Small Cell Lung Cancer (SCLC)","Colorectal Carcinoma (CRC)","Triple -Negative Breast Cancer","Pancreas Adenocarcinoma",[68,69,70,71,72,73,74,75],"THE-0504","Solid tumors","Cancer","Single-centre","Thena Biotech","Italy","Phase 1","Europe","2026-06-09",{"date":78,"type":42},"2026-06-12",{"date":80,"type":42},"2024-11-13",{"date":82,"type":22},"2027-05-01",{"name":84,"class":49},"Thena Biotech S.r.l.",1,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100576736","phase-1-a-phase-1-first-in-human-study-of-okn4395-and-pembrolizumab-in-patients-with-solid-tumors-100576736","NCT06789172","A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors","A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors","INVOKE","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed disease, locally advanced or metastatic:\n\n   For Phase 1a:\n\n   Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are not available, no longer effective, refused or not tolerated.\n\n   For Phase 1b:\n\n   For all cohorts, in the opinion of the investigator, all appropriate authorized treatment options should be exhausted\n   * Cohort 1: Sarcoma (fibrous sarcoma \\[myxofibrosarcoma or solitary fibrous tumor\\], dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma or pleomorphic sarcoma, or leiomyosarcoma), that is either refractory to or progressing on standard of care, with no more than 3 prior lines of systemic therapy. Patients with a solitary fibrous tumor can be included in the study without prior treatment if, in the investigator's opinion, it is in the participant's best interest and no established standard of care exists or is available.\n   * Cohort 2: NSCLC (squamous or adenomatous without EGFR\u002FALK mutations), with disease progression on a PD-(L)1 CPI regimen, and no more than 3 prior lines of systemic therapy. When known, PD-L1 status should be provided.\n   * Cohort 3: CRC (Microsatellite stable or Microsatellite instability - low), and no more than 4 prior lines of systemic therapy.\n   * Cohort 4: GC (gastric and gastro-esophageal junction adenocarcinoma), HER2-negative, planned to or currently receiving CPI monotherapy as maintenance of a first-line CPI + chemotherapy regimen, after chemotherapy cessation.\n2. ECOG performance status of 0 or 1.\n3. Recovery from any medically relevant AE\u002FirAE from previous treatment regimen (defined as recovery to Grade ≤1 level per CTCAE v 5.0 before Screening, or chronic, stable, Grade 2 AEs \\[not worsened to Grade \\>2 for \\>3 months prior to screening\\]).\n4. One or more new or growing tumor lesions amenable to a safe biopsy (at baseline, a suitable archival specimen obtained when not undergoing treatment and within 1 year \\[Phase 1a\\], or within 90 days and after the last administration of the previous systemic therapy \\[Phase 1b\\] is suitable). In addition (where applicable) an archival tumor biopsy collected before the start of the first-line treatment in the metastatic setting is requested (but optional).\n5. At least one target lesion measurable by RECIST 1.1 as noted by local investigators\u002Fradiologists.\n6. The ability to swallow and retain OKN4395 as an oral medication without significant gastrointestinal abnormalities that might alter absorption.\n7. The willingness and ability to comply with the evaluation, randomizations and requirements of the protocol. For Substudy 1, the ability to comply with the evaluation requirements includes the absence of any condition known to affect upper gastrointestinal motility, absorption, and pH.\n8. Adequate hematologic, renal, and hepatic function (based on local laboratory assessments):\n\n   1. Hematological variables: absolute neutrophil counts ≥1.5 × 109 \u002FL, platelet counts ≥75 × 109 \u002FL, and hemoglobin ≥8 g\u002FdL\n   2. Renal variables: creatinine clearance ≥ 60 mL\u002Fmin1 by Du Bois \\& Du Bois formula\n   3. Hepatic variables: total serum bilirubin ≤1.5 × ULN, AST and ALT ≤3 × ULN, and ALP ≤2.5 × ULN; except for hyperbilirubinemia of Gilbert's syndrome (participants with Gilbert's syndrome can be included if total serum bilirubin ≤5× ULN and direct bilirubin ≤1.5 x ULN)\n   4. Serum albumin ≥30 g\u002FL\n\nExclusion Criteria:\n\n1. Except for the current regimen in Cohort 4, ongoing or recent anticancer therapy within the following timeframe prior to first dose of study drug:\n\n   1. Chemotherapy, ADCs, or other antibodies \\\u003C 21 days\n   2. Immunotherapy or cellular therapy \\\u003C 28 days\n   3. Radiation therapy (palliative radiation for bone pain \\\u003C48 hours; stereotactic or small field brain irradiation \\\u003C7 days; all other radiation therapy \\\u003C14 days)\n   4. TKI or any other anticancer therapy \\\u003C 5 half-lives or \\\u003C 7 days, whichever is longer\n2. Central nervous system metastasis (radiologically progressive, or clinically symptomatic, or requiring immunosuppressive therapies \\[including low dose steroids\\]).\n3. Any active infection (bacterial, viral, fungal) requiring IV systemic therapy.\n4. Unstable COPD defined as frequent or severe exacerbations per investigator discretion.\n5. Known history of or active HBV (HBsAg reactive and\u002For HBV DNA detected) or HCV (HCV RNA detected) infection.\n6. HIV infection with CD4 lymphocyte count \\\u003C350 cells\u002FμL at time of Screening, or failure to achieve and maintain virologic suppression defined as confirmed HIV RNA level \\\u003C 50 or lower limit of detection by the local available assay at time of Screening and for at least 12 weeks prior to Screening.\n7. Known history of bleeding disorders, INR ≥1.5 × ULN at screening (or INR and\u002For aPTT within therapeutic range if on anticoagulation therapy), or a history of gastrointestinal bleeding (inflammatory, ulcerative, or diverticular) within the last 2 years.\n8. Known H. pylori infection without proof of eradication at least 2 months prior to screening.\n9. Systemic treatment with any drug known to impact gastrointestinal pH within 7 days (PPIs) or 12 hours (H2 antagonists) of first dose of OKN4395 (unless adapted after Substudy 1). Where said treatments have been used for more than 2 weeks prior to discontinuation, discontinuation should occur at least 21 days before first dose of OKN4395.\n10. Acute treatment with any systemic steroid therapy (\\>10 mg prednisone equivalent), or any corticosteroid medication within 14 days of first dose of OKN4395 for any condition.\n11. For participants planned to receive combination therapy: Ongoing and history of active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Any replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed. Participants with hyperthyroidism or hypothyroidism but that are stable on hormone replacement are also allowed.\n12. Systemic treatment with NSAIDs, COX2 inhibitors, or synthetic prostaglandins within 5 half-lives prior to the first dose of OKN4395 (acetylsalicylic acid ≤ 160 mg\u002Fday, or 325 mg ≤ 3 times\u002Fweek is permitted).\n13. Systemic treatment with strong inhibitors\u002Finducers of CYP and UGT enzymes within 14 days of first dose of OKN4395.\n14. QTcF interval of \\> 450 ms based on mean of the central triplicate readings.\n15. Known hypersensitivity to any excipients of the OKN4395 formulation or pembrolizumab (for combination cohorts).\n16. Pregnant or lactating women. Women of childbearing potential must have a negative serum pregnancy test at screening and have a negative a urine dipstick pregnancy test prior to the initiation of study treatment (can be done on C1-D1 visit).\n17. Evidence of any other active malignancy requiring systemic therapy within the 2 years prior to Screening. (Exceptions: non-melanoma skin cancer, in situ melanoma, in situ cervical cancer, ductal carcinoma in situ of the breast, or localized and presumed cured prostate cancer; participants on long-term anti-hormonal therapy for a prior malignancy are allowed if the malignancy has not been active within the prior 2 years).\n18. History or current evidence of any condition, surgical or medical therapy, or laboratory abnormalities that might confound the results of the study, make study drug administration hazardous, interfere with the participant's involvement for the full duration of the study, or make it difficult to monitor AEs such that, in the opinion of the treating physician, it is not in the best interest of the participant to participate",{"count":95,"type":22},146,[60],"The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab.\n\nThe overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab.\n\nThis study will be split into 2 parts. Part 1a will look at multiple doses of OKN4395 either alone (monotherapy) or with pembrolizumab (combination therapy) administered on day 1 of each 21-day cycle in patients with solid tumors until the participant has disease progression or discontinues for any reason. The dose of OKN4395 will be increased, after each group of 3 or more participants completes their first 3 weeks of treatment and their data is evaluated for safety, with a planned dose range from 10 mg twice a day to 450 mg twice a day through 13 dose levels. Part 1a also includes a parallel substudy (Substudy 1) consisting of at least 12 participants, aiming to test the effect of food and stomach acid on the levels of OKN4395 in the blood as well as its tolerability.\n\nPart 1b will evaluate OKN4395 alone and in combination with pembrolizumab administered on day 1 of each 21-day cycle in patients with selected cancer types. Part 1b will comprise 4 cohorts: Cohort 1 in sarcoma (OKN4395 alone), Cohort 2 in non-small cell lung cancer (NSCLC), Cohort 3 in colorectal cancer, and Cohort 4 in gastric cancer (GC), with cohorts 2 to 4 in combination with pembrolizumab.\n\nThe overall study will enrol approximately 146 participants with up to 54 participants to receive OKN4395 alone and 12 participants to receive OKN4395 in combination with pembrolizumab in Part 1a, and 80 participants in Part 1b split: 20 on monotherapy and 60 on combination therapy.\n\nThe study will be conducted in the US, Australia, UK and in the EU.",[99,100,101,102,103,104,105,106,107,108,109,110,29,111,112],"Solid Tumours","Sarcoma","HNSCC","Non Small Cell Lung Cancer","NSCLC","Colorectal Cancer (CRC)","Myxofibrosarcoma (MFS)","Solitary Fibrous Tumors","Dedifferentiated Liposarcoma","Undifferentiated Pleomorphic Sarcoma (UPS)","Leiomyosarcoma","Leiomyosarcoma (LMS)","Gastric Cancer Adenocarcinoma Metastatic","Gastric \u002F Gastroesophageal Junction Adenocarcinoma",{"date":114,"type":42},"2026-06-11",{"date":116,"type":42},"2025-01-23",{"date":118,"type":22},"2028-09",{"name":120,"class":49},"Epkin",10,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":85},"100643800","comparison-of-double-tract-and-tubular-gastric-anastomosis-in-proximal-gastric-cancer-100643800","NCT07635836","Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer","Comparison of Gastroesophageal Reflux and Quality of Life Between Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer Patients","Inclusion Criteria:\n\n* Pathologically confirmed gastric adenocarcinoma by biopsy\n* Carcinoma of the upper gastric body or Siewert type II\u002FIII adenocarcinoma of the esophagogastric junction (AEG), with a clinical stage of cT1-3N0-1M0\n* Age 18-75 years, with a performance status (PS) score of 0-2\n* Candidates for planned surgical resection, eligible for either double-tract reconstruction or tubular gastric anastomosis based on preoperative assessment\n* No severe dysfunction of vital organs (liver, kidney, heart, lung, or brain), and no severe infection or uncontrolled chronic diseases\n\nExclusion Criteria:\n\n* Presence of other malignant tumors or severe chronic diseases (e.g., severe diabetes mellitus, chronic kidney disease, decompensated cirrhosis, etc.)\n* Preoperative endoscopic diagnosis of Barrett's esophagus\n* Severe preoperative malnutrition (albumin \\\u003C30 g\u002FL, prealbumin \\\u003C150 mg\u002FL)\n* History of prior upper abdominal surgery, gastrointestinal malformation, or psychiatric disorders\n* Preoperative diagnosis of obstructive motor disorders of the cardia (including achalasia spectrum disorders)\n* Inability to cooperate with or complete the required postoperative examinations","75 Years",{"count":131,"type":22},52,[133],"NA","This study includes patients diagnosed with proximal gastric cancer (Siewert type II\u002FIII, cT1-3N0-1M0) across six tertiary hospitals, who underwent either double-tract reconstruction (DTR) or tubular gastric anastomosis (TGA). Participants were divided into two groups based on the surgical procedure. We conducted a comparative analysis of postoperative outcomes by evaluating electronic medical records, postoperative gastroscopy, 24-hour esophageal pH monitoring, and relevant rating scales.",[29,136,137],"Double-tract Reconstruction","Tubular Gastric Anastomosis","2026-06-03",{"date":76,"type":42},{"date":141,"type":42},"2026-05-01",{"date":143,"type":22},"2027-10-01",{"name":145,"class":146},"Qilu Hospital of Shandong University","OTHER",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":154,"sex":18,"minAge":155,"maxAge":4,"enrollmentInfo":156,"targetDuration":158,"studyType":159,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100637944","ai-based-risk-prediction-model-for-upper-digestive-tract-cancer-100637944","NCT07605312","AI-Based Risk Prediction Model for Upper Digestive Tract Cancer","Development of Artificial Intelligence Risk Prediction Model for Upper Digestive Tract Cancer Using High Resolution Endoscopic Image, Digital Pathology, Genetics, and Oro-gastro-intestinal Microbiota.","Inclusion Criteria:\n\n* Patients undergoing upper gastrointestinal endoscopy.\n* Patients with at least one of the following conditions or indications:\n\n  * Previous or current Helicobacter pylori infection (confirmed by serology, histopathology, urea breath test, rapid urease test, or stool antigen test);\n  * Dyspeptic symptoms;\n  * Gastroesophageal reflux disease;\n  * History of oral, oropharyngeal, or hypopharyngeal squamous cell carcinoma;\n  * Barrett's esophagus;\n  * Gastric premalignant lesions (intestinal metaplasia or atrophic gastritis);\n  * Gastric subepithelial lesions.\n\nExclusion Criteria:\n\n\\-",true,"40 Years",{"count":157,"type":22},10000,"10 Years","OBSERVATIONAL","Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development. This prospective multicenter cohort study aims to establish a longitudinal database integrating clinical information, endoscopic findings, pathology, genetics, epigenetics, and gastrointestinal microbiota data from subjects undergoing upper digestive tract endoscopy.\n\nThe study will develop explainable artificial intelligence (AI)-based risk prediction models to identify factors associated with disease progression, treatment response, and cancer development. Participants will be followed longitudinally to evaluate changes in lesion severity and clinical outcomes.",[29,162,163,164,165,166],"Premalignant Lesion","Gastric Intestinal Metaplasia","Atrophic Gastritis","Dysplasia Stomach","Esophageal Cancer (EsC)","NOT_YET_RECRUITING","2026-05-25",{"date":170,"type":42},"2026-05-28",{"date":172,"type":22},"2026-05-18",{"date":174,"type":22},"2030-05-18",{"name":176,"class":146},"National Taiwan University Hospital",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":85},"100637359","a-study-on-the-efficacy-of-sodium-propionate-combined-with-anti-pd-1-immunotherapy-in-gastric-cancer-100637359","NCT07615907","A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer","Sodium Propionate Combined With Anti-PD-1 Immunotherapy on Tumor Efficacy in Gastric Cancer Patients","PAPGC","Inclusion Criteria:\n\n* Subjects voluntarily participated in the trial and signed the informed consent form;\n* Aged ≥ 18 years and \\\u003C 80 years, regardless of gender;\n* Stable vital signs;\n* Patients with gastric adenocarcinoma confirmed by gastroscopic biopsy;\n* Tumors judged as unresectable by attending physicians;\n* Receiving anti-PD-1 therapy combined with chemotherapy as first-line treatment;\n* No history of allergic diseases and non-allergic constitution;\n* No history of drug abuse;\n* Non-pregnant and non-lactating females (applicable to male subjects as well);\n* No participation in any drug clinical trial (including investigational drugs of this trial) within 3 months prior to enrollment.\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria, or individuals deemed inappropriate for trial participation by investigators;\n* Concurrent primary malignant tumors at other sites;\n* Poor general condition, severe infection, respiratory insufficiency, or other conditions leading to inability to cooperate with the trial;\n* Patients with mental disorders, consciousness disturbance, or poor treatment compliance;\n* Suspected or confirmed history of drug abuse;\n* Immunodeficiency, or long-term use of immunosuppressants and glucocorticoids;\n* Pregnant or lactating women;\n* Sponsors, investigators directly involved in this trial, and their immediate family members;\n* Individuals unsuitable for enrollment for any reason as judged by the investigator.","80 Years",{"count":187,"type":22},20,[133],"Eligible patients were randomized into two groups: the sodium propionate group and the control group. In the control group, patients received placebo combined with anti-PD-1 therapy plus chemotherapy without additional sodium propionate intervention. In the sodium propionate group, on the basis of anti-PD-1 therapy combined with chemotherapy, patients were additionally administered oral sodium propionate capsules at a dose of 500 mg (1 capsule) twice weekly, with a total intervention duration of 12 weeks. The primary and secondary outcome indicators will be collected for subsequent analysis.",[29],[192,193,194],"Gastric cancer","Sodium propionate","Immunotherapy",{"date":196,"type":42},"2026-05-29",{"date":198,"type":22},"2026-05-30",{"date":46,"type":22},{"name":201,"class":146},"Jinling Hospital, China",{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":218,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100639609","phase-1-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-xh001-injection-as-adjuvant-therapy-in-patients-with-high-risk-recurrent-solid-tumors-100639609","NCT07594964","To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors","Phase I Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors After Radical Surgery","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form;\n* Aged between 18 and 70 years old, male or female;\n* Patients with high-risk recurrent solid tumors confirmed by pathology after radical surgery mainly include pancreatic ductal adenocarcinoma, biliary tract malignancies, hepatocellular carcinoma, gastric adenocarcinoma, etc.\n* Expected survival duration ≥12 months;\n* ECOG score of 0-1;\n* White blood cell count≥ 3.0×10\\^9\u002FL; Neutrophil count ≥ 1.0×10\\^9\u002FL; Platelet count ≥75×10\\^9\u002FL; Hemoglobin (Hb)≥ 90g\u002FL; Creatinine clearance rate≥50mL\u002Fmin \\[calculated using the Cockcroft-Gault formula\\]; Alanine aminotransferase ≤ 3×ULN (patients with hepatocellular carcinoma or biliary tract malignancy \\\u003C5×ULN); Aspartate aminotransferase ≤ 3×ULN ((patients with hepatocellular carcinoma or biliary tract malignancy \\\u003C5×ULN); Total bilirubin ≤ 3×ULN; Serum albumin \\> 28g\u002FL; Coagulation: Prothrombin time prolongation ≤ 4s;\n\nExclusion Criteria:\n\n* There is evidence of tumor residue, recurrence or metastasis during screening;\n* Has a history of hepatic encephalopathy or liver transplantation;\n* Has clinical uncontrolled (requiring repeated drainage) pericardial effusion, pleural effusion and moderate or severe ascites;\n* Requires long-term systemic administration of antiallergic drugs, or has severe hypersensitivity reactions (\\>=Grade 3) to XH001 injection and\u002For any of its excipients;\n* New cerebrovascular accidents within 6 months before screening (including ischemic stroke, hemorrhagic stroke and transient ischemic attack)；\n* Individuals who have experienced acute myocardial infarction, or have uncontrolled angina pectoris, uncontrolled arrhythmia, severe heart failure (NYHA heart failure classification standard\\>= Grade III) and other cardiovascular diseases within 6 months before screening;\n* Patients with pancreatic ductal adenocarcinoma (PDAC) have the following conditions: 1) Borderline resectable pancreatic ductal adenocarcinoma; 2) Tumor tissue containing neuroendocrine tumor components (i.e., mixed type); 3) Pancreatic tumor types other than PDAC; 4) Persistent severe diarrhea after surgery;\n* Patients with biliary tract malignancy have the following conditions: 1) Pancreatic or ampullary cancer; 2) Unresolved biliary obstruction; 3) Insufficient surgical biliary drainage, and there are signs of infection;\n* .Subjects with hepatocellular carcinoma exhibit the following conditions: 1) The tumor contains components such as fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, and biliary tract malignancy; 2) Received more than one cycle of adjuvant TACE after surgery or ablation;\n* Patients with gastric adenocarcinoma have the following conditions: severe postoperative complications (severe postoperative infection, anastomotic leakage and gastrointestinal bleeding);\n* Have active or poorly controlled severe infections;\n* .Patients with other malignancies within 5 years before enrollment, except for those with a history of appropriately treated and cured cervical carcinoma in situ, breast carcinoma in situ, or skin basal cell carcinoma;\n* Any history of autoimmune diseases (regardless of whether they are currently active),；\n* Who have previously received similar therapeutic tumor vaccines;","70 Years",{"count":211,"type":22},48,[60],"The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with high-risk recurrent solid tumors after radical surgery.\n\nThe main questions it aims to answer are: What medical problems do participants have when using the combined treatment? Does XH001 injection combined with standard adjuvant treatment induce a specific T-cell response, and can it prolong the patient's relapse-free survival?",[215,216,217,29],"Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)","Pancreatic Ductal Adenocarcinoma (PDAC)","Hepatocellular Carcinoma (HCC)",[219,220],"mRNA","Neoantigen specific tumor vaccine",{"date":222,"type":42},"2026-05-19",{"date":224,"type":42},"2025-08-25",{"date":226,"type":22},"2030-06-30",{"name":228,"class":49},"Shenzhen Xinhe Biomedical",2,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100638271","a-subharmonic-aided-pressure-estimate-technology-for-prediction-of-response-to-systemic-therapy-in-gastric-cancer-liver-metastases-100638271","NCT07581730","A Subharmonic-Aided Pressure Estimate Technology for Prediction of Response to Systemic Therapy in Gastric Cancer Liver Metastases","A Prospective Study of a Subharmonic-Aided Pressure Estimate Technology for Early Prediction of Response to Systemic Therapy in Gastric Cancer Liver Metastases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or radiologically confirmed, initially diagnosed and have not undergone any treatment gastric liver metastasis (GCLM).\n* Lesion size ≤ 6 cm (preferably located adjacent to major anatomical structures such as large vessels or bile ducts).\n* Lesion depth ≤ 10 cm on ultrasound imaging.\n* Planned to receive guideline-recommended first-line systemic therapy.\n* The target lesion has not undergone any prior systemic or local treatment, including surgery, ablation, embolization, targeted therapy, or investigational agents, before enrollment.\n* Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to cooperate with contrast-enhanced ultrasound or subharmonic imaging examinations (e.g., dyspnea when lying supine or excessive out-of-plane motion).\n* Know or suspected allergy to the contrast agent or other contraindications to its use.\n* Target lesion not previously evaluated or managed according to standard systemic treatment protocols.\n* Clinically unstable condition, advanced-stage disease, or patients with an unpredictable clinical course that may affect treatment tolerance or follow-up.\n* Pregnant or breastfeeding women. 6.Inability to understand or comply with the study protocol, including the requirement to complete follow-up visits and examinations.",{"count":238,"type":22},107,"Gastric cancer is a common type of cancer that often spreads to the liver. When cancer spreads to the liver, treatment becomes very difficult. Many patients will undergo chemotherapy to shrink the tumor. Currently, doctors use CT or MRI scans to assess the effect of chemotherapy, but these examinations usually take about 2 months to show changes in the size of the tumor.\n\nThe purpose of this study is to test whether a special type of ultrasound technology called \"contrast-enhanced subharmonic ultrasound\" can help doctors determine earlier whether chemotherapy is effective compared to conventional scans. This ultrasound detection does not use radiation and can display the blood perfusion status inside liver tumors. We will observe the changes in blood flow perfusion inside the tumor before the start of treatment and after 1-2 chemotherapy cycles to see if these changes can predict whether chemotherapy will be effective in the future.\n\nIf this test is effective, it will help doctors adjust the treatment plan more quickly, which may improve the treatment effect for gastric cancer patients whose cancer cells have spread to the liver, and also help identify patients who are not responding to chemotherapy as early as possible, reducing the side effects and economic burden of patients.",[241,29,242],"Liver Neoplasms","Gastric Cancer Metastatic to Liver",[244,245,246,247,248,249],"Gastric cancer liver metastasis","Contrast-enhanced ultrasound","Subharmonic imaging","Chemotherapy response prediction","Early treatment response","Perfusion imaging",{"date":251,"type":42},"2026-05-20",{"date":141,"type":22},{"date":254,"type":22},"2027-12-01",{"name":256,"class":146},"The First Hospital of Jilin University",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":284},"100623789","multimodal-ai-for-predicting-response-to-neoadjuvant-immunotherapy-in-gastric-cancer-prism-gc-100623789","NCT07401199","Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","A Prospective, Multicenter, Real-World Cohort Study for the Development and Validation of a Multimodal Artificial Intelligence System to Predict Response to Neoadjuvant Chemo-Immunotherapy in Locally Advanced Gastric Cancer (The PRISM-GC Study)","Inclusion Criteria:\n\nAge ≥ 18 years.\n\nHistologically confirmed gastric or gastroesophageal junction adenocarcinoma.\n\nClinical stage cT3-4a, N+, M0 (locally advanced) assessed by CT\u002FMRI and endoscopic ultrasound.\n\nScheduled to receive neoadjuvant chemotherapy combined with PD-1 inhibitors (regimens including but not limited to SOX\u002FXELOX + Sintilimab\u002FTislelizumab\u002FCamrelizumab, etc.) as standard of care.\n\nAvailability of standard pre-treatment contrast-enhanced abdominal CT images.\n\nWillingness to provide peripheral blood samples and tumor tissue (biopsy\u002Fsurgical) for sequencing and analysis.\n\nECOG performance status 0-1.\n\nAdequate organ function to tolerate systemic chemotherapy.\n\nExclusion Criteria:\n\nEvidence of distant metastasis (Stage IV) or unresectable disease.\n\nPrevious systemic anti-tumor therapy for gastric cancer (chemotherapy, radiotherapy, or immunotherapy).\n\nHistory of other malignancies within the past 5 years.\n\nActive autoimmune diseases requiring systemic immunosuppressive treatment (contraindication for PD-1 inhibitors).\n\nEmergency surgery due to obstruction, perforation, or uncontrolled bleeding.\n\nSevere metallic artifacts on CT images that interfere with radiomic feature extraction.\n\nPregnancy or lactation.",{"count":265,"type":22},2000,"Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy. While this approach is effective for many patients, responses vary significantly, and there are currently no reliable tools to predict which patients will benefit the most before treatment begins.\n\nThe PRISM-GC study aims to develop and validate a novel Artificial Intelligence (AI) system to address this need. This is a prospective, observational study that will collect data from patients diagnosed with locally advanced gastric cancer who are scheduled to receive standard neoadjuvant chemotherapy combined with immunotherapy in a real-world clinical setting. The specific choice of immunotherapy drug is determined by the treating physician and is not dictated by the study.\n\nResearchers will analyze standard preoperative CT scans and pathological tissue slides using advanced deep learning algorithms. The goal is to create a \"multimodal\" AI model that can accurately predict how well a tumor will respond to treatment (specifically, whether the tumor will disappear or shrink significantly). If successful, this AI tool could help doctors personalize treatment plans in the future, ensuring that each patient receives the most effective therapy while avoiding unnecessary side effects.",[29,268],"Locally Advanced Gastric Cancer",[270,271,272,273,274],"Neoadjuvant Immunotherapy","Artificial Intelligence","Deep Learning","Pathological Complete Response","PD-1 Inhibitors","2026-05-13",{"date":277,"type":42},"2026-05-15",{"date":279,"type":42},"2026-02-05",{"date":281,"type":22},"2027-12-30",{"name":283,"class":146},"Qun Zhao",9,{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":4},"100639312","prediction-of-peritoneal-dissemination-of-digestive-tumors-through-the-study-of-circulating-tumor-dna-100639312","NCT07574957","Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA","Prédiction de la dissémination péritonéale Des Tumeurs Digestives Par étude de l'ADN Tumoral Circulant","PREDIPER","Inclusion Criteria:\n\n* Age \\> 18 years\n* Signed non-opposition form\n* For gastric cancer: histologically confirmed gastric adenocarcinoma \\>T2 and\u002For N+; for colon cancer: histologically confirmed colonic adenocarcinoma \\>T2; for pancreatic cancer: histologically confirmed pancreatic adenocarcinoma \\>T2\n* No metastases on the initial staging work-up\n* No contraindication to curative-intent surgical treatment\n\nExclusion Criteria:\n\n* Primary tumor metastatic at diagnosis\n* Presence of ascites or distant metastases\n* Synchronous cancer or prior history of cancer within the past 5 years\n* Contraindication to curative surgical treatment\n* Any patient unable to comply with the study's medical follow-up for geographic, social, or psychological reasons\n* Patients under legal guardianship\u002Fprotection, or unable to read, understand, and sign the information notice and consent form\n* Patients not affiliated with the social security system",{"count":294,"type":22},300,"The peritoneum is a relatively frequent metastatic site in digestive tumors (colon, stomach, pancreas) and is characterized by a poorer prognosis compared with other metastatic sites such as the lung or liver. Its dissemination pathway is complex and most often involves crossing the hemato-peritoneal barrier. This type of metastasis is difficult to visualize on imaging at an early stage, and surgical exploration may be required. In gastric cancer in particular, exploratory laparoscopy is part of the initial staging work-up for locally advanced tumors to assess the presence or absence of peritoneal metastases. It is therefore important to develop new, less invasive detection or prediction methods.\n\nCirculating tumor DNA (ctDNA) is a promising non-invasive blood biomarker that can assist clinicians as a prognostic\u002Fpredictive biomarker and\u002For a tool for monitoring response to anti-tumor therapies. This marker is most often assessed in plasma, but recent data suggest that tumor DNA may also be detected in other biological fluids such as peritoneal fluid. A preliminary study conducted by our team showed the ability to detect tumor DNA in peritoneal fluid from patients with peritoneal carcinomatosis of various origins, with a sensitivity of 75%. In gastric cancer, a recent meta-analysis demonstrated an increased risk of peritoneal metastases when peritoneal tumor DNA was positive (RR 13.81 \\[95% CI, 8.11-23.53\\]), as well as a reduction in 3-year recurrence-free survival (RR 5.37 \\[95% CI, 1.39-20.74\\]) and overall survival (HR 4.13 \\[95% CI, 1.51-11.32\\]).\n\nThe objective of this cohort is to evaluate the prognostic impact of circulating tumor DNA (ctDNA) in plasma and\u002For peritoneal fluid on the risk of developing peritoneal metastases. The primary endpoint is: Peritoneal recurrence rate according to tumor DNA positivity status (positive vs negative).",[29,297,298],"Pancreatic Cancer","Colorectal Cancer","2026-05-05",{"date":301,"type":42},"2026-05-08",{"date":303,"type":22},"2026-06-01",{"date":305,"type":22},"2033-06-01",{"name":307,"class":146},"Assistance Publique - Hôpitaux de Paris",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":85},"100626911","immediate-and-functional-results-of-different-types-of-reconstructions-after-proximal-gastrectomy-for-gastric-and-esophagogastric-junction-cancer-100626911","NCT07441785","Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer","PROXISTAT","Inclusion Criteria:\n\n* All consecutive patients with clinically documented primary Gastric or Esophagogastric Junction malignancy (including Siewert I and II) cT1-3N0-2M0 undergoing proximal gastrectomy with curative intent - via open, laparoscopic or robotic approach between 01th January 2025 and 31th December 2026\n\nExclusion Criteria:\n\n* Patients with clinical evidence of metastatic disease, including positive peritoneal cytology on a previous staging laparoscopy, or those with known synchronous other cancers.\n* Esophagogastric Junction Siewert I malignancy\n* Patients submitted to Emergency surgery or surgery without curative intent\n* Patients undergoing any other surgery in addition to the curative surgery for primary Esophageal or Esophagogastric Junction malignancy\n* Patients who have previously undergone surgery on the stomach or colon",{"count":316,"type":22},400,"Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to significant functional issues.\n\nRising use of proximal resections and broader indications have increased attention to postoperative quality of life (QoL). Common reconstructions include direct esophagogastrostomy (various types), double-tract reconstruction, jejunal interposition, and newer anti-reflux anastomoses (e.g., double-flap, overlap, tunnel techniques).\n\nEach method has unique pros and cons regarding reflux esophagitis, food passage, dumping syndrome, nutritional changes, and long-term QoL.\n\nNo consensus exists on the optimal technique, leading to variable practices and outcomes. Most research focuses on oncologic radicality and survival, while functional results and QoL remain understudied.\n\nSystematic evaluation of functional outcomes across reconstruction types after proximal subtotal gastrectomy is needed in Russian Federation to improve QoL, advance research, and standardize treatment of proximal gastric and EGJ cancers.",[29,319,320],"Siewert Type III Adenocarcinoma of Esophagogastric Junction","Siewert Type II Adenocarcinoma of Esophagogastric Junction",[322,323,324,325,326,327],"Proximal gastrectomy","Morbidity","Mortality","Quality of life","Surgery","Esophagogastric Junction Cancer","2026-04-17",{"date":330,"type":42},"2026-04-22",{"date":332,"type":42},"2025-01-01",{"date":334,"type":22},"2029-06-01",{"name":336,"class":337},"P. Herzen Moscow Oncology Research Institute","OTHER_GOV",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":129,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":347,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100632587","phase-2-efficacy-of-sintilimab-combined-with-bevacizumab-and-xeloxsox-in-initially-unresectable-afp-positive-gastricgastroesophageal-junction-adenocarcinoma-100632587","NCT07515625","Efficacy of Sintilimab Combined With Bevacizumab and XELOX\u002FSOX in Initially Unresectable AFP-positive Gastric\u002FGastroesophageal Junction Adenocarcinoma","Conversion Therapy of Sintilimab Combined With Bevacizumab and XELOX\u002FSOX for Initially Unresectable AFP-positive Gastric\u002FEsophagogastric Junction Adenocarcinoma : A Multi-center, Single-arm, Phase II Trial (SOLIDS-02)","Inclusion Criteria:\n\n* Signed informed consent;\n* Patients age 18-75 years;\n* Histologically CT\u002FMRI confirmed cT3-4N+M0\u002F1 gastric or GEJ adenocarcinoma; (M1 only includes type I liver metastasis of gastric cancer, according to the \"Chinese Expert Consensus on Liver Metastasis of Gastric Cancer\");\n* Serum AFP levels \\> 2× upper limit of normal or AFP-positive by IHC staining;\n* Adequate organ function\n* ECOG 0-1, no surgery contraindications;\n* Expected survival ≥3 months;\n\nExclusion Criteria:\n\n* HER2-positive status: IHC 3+, or IHC 2+\u002FFISH+\n* Prior chemotherapy, radiotherapy, anti-PD-1\u002FPD-L1 therapy, surgery for gastric cancer;\n* Signs of other distant metastases (e.g., peritoneal, lung, bone, supraclavicular lymph, etc.)\n* Significant cardiovascular disease\n\n  --Current treatment with anti-viral therapy or HBV\n* Pregnancy or breastfeeding\n* History of malignancy within 5 years prior to screening\n* Present or history of any autoimmune disease or immune deficiency;\n* There are active gastric and duodenal ulcers, ulcerative colitis and other gastrointestinal diseases, or active bleeding in unresectable tumors.",{"count":346,"type":22},46,[348],"PHASE2","Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases. Its clinical features are significantly different from those of common gastric cancer. Not only does it show abnormally elevated serum AFP levels, but it also has a stronger angiogenic ability, a higher rate of distant metastasis, and a poorer prognosis even after a upfront R0 surgery, making it a challenging problem in the field of gastric cancer treatment. Notably, patients with AFP-positive gastric cancer have a relatively low sensitivity to the traditional standard regimens. There is an urgent need to explore targeted treatment strategies to break through the efficacy bottleneck.\n\nCombination of sintilimab, bevacizumab and XELOX\u002FSOX for initially unresectable AFP-positive gastric\u002Fesophagogastric junction adenocarcinoma could be a novel therapeutic strategy to increase response rate and therapeutic efficacy. This study is a multi-center, single-arm phase 2 clinical trial to evaluate efficacy, tolerability and safety of perioperative sintilimab in combination with bevacizumab and XELOX\u002FSOX in initially unresectable AFP-positive gastric\u002Fesophagogastric junction adenocarcinoma.",[29,351],"AFP Gastric or Gastroesophageal Junction Adenocarcinoma","2026-03-30",{"date":354,"type":42},"2026-04-07",{"date":356,"type":22},"2026-04-01",{"date":358,"type":22},"2029-04-01",{"name":360,"class":146},"Fudan University",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":129,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":379,"leadSponsor":381,"locationsCount":4},"100631541","phase-4-a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-sox-following-heterogeneous-radiotherapy-as-first-line-treatment-for-unresectable-locally-advanced-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction-adenocarcinoma-100631541","NCT07502027","A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma","A Multicenter, Single-arm, Exploratory Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Age 18-75 years, male or female.\n* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.\n* Patients with no prior systemic therapy for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. For patients who received neoadjuvant or adjuvant chemotherapy or chemoradiotherapy with curative intent, the interval from the last treatment to disease progression must be at least 6 months.\n* HER-2 negative (IHC 1+ or IHC 2+\u002FFISH-negative).\n* Presence of radiation-eligible tumor lesions.\n* No anticipated need for tumor resection during the study treatment period.\n* ECOG performance status 0-1.\n* At least one measurable lesion per RECIST v1.1. Lesions that have received prior radiotherapy cannot be selected as target lesions unless they are the only measurable lesions and show unequivocal progression on imaging, in which case they may be considered as target lesions.\n* Expected overall survival ≥ 3 months.\n* Adequate function of major organs.\n\nExclusion Criteria:\n\n* Presence of other histologic components confirmed by histopathology or cytology, such as squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, etc.\n* Prior treatment with any tumor immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or immune cell therapy (e.g., CAR-T cells).\n* Palliative local therapy to non-target lesions within 2 weeks before the first dose; or systemic non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin) within 2 weeks before the first dose.\n* Clinically significant pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1 time per month).\n* Known active or untreated brain metastasis, meningeal metastasis, spinal cord compression, or leptomeningeal disease. Patients with measurable lesions outside the central nervous system may be eligible if: they are asymptomatic after treatment, radiologically stable for at least 4 weeks before study treatment (no new or enlarging brain metastases), and have discontinued systemic corticosteroids and anticonvulsants for at least 2 weeks.\n* Gastrointestinal perforation, gastrointestinal fistula, or intra-abdominal abscess within 6 months before the first dose.\n* Clinically significant bleeding or definite bleeding diathesis within 6 months before the first dose, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or vasculitis, excluding asymptomatic positive fecal occult blood.\n* Arterial or venous thromboembolism within 6 months before the first dose, including cerebrovascular accident (transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary embolism, etc. Superficial venous thrombosis is permitted.\n* Clinically active hemoptysis or active diverticulitis.\n* Major surgery other than for gastric cancer diagnosis within 28 days before the first dose, or anticipated major surgery during the study period.\n* Severe infection (CTCAE grade \\> 2) within 4 weeks before the first dose, such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; active lung inflammation on baseline chest imaging; or signs\u002Fsymptoms of infection or oral\u002Fintravenous antibiotic therapy within 14 days before the first dose, excluding prophylactic antibiotics.\n* Any active or history of autoimmune disease, including but not limited to: interstitial lung disease, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism. Hypothyroidism may be allowed if controlled by hormone replacement. Patients with fully resolved psoriasis or childhood asthma\u002Fallergies requiring no intervention in adulthood may be included; those requiring medical intervention with bronchodilators are excluded.\n* History of immunodeficiency, including positive HIV test, other acquired or congenital immunodeficiency diseases, organ transplantation, or allogeneic bone marrow transplantation.\n* Uncontrolled cardiac conditions, including but not limited to:\n\n  1. NYHA class ≥ II heart failure;\n  2. unstable angina;\n  3. myocardial infarction within 1 year;\n  4. clinically significant supraventricular or ventricular arrhythmia uncontrolled or poorly controlled despite intervention;\n  5. QTc \\> 450 ms (male); QTc \\> 470 ms (female).\n* Active tuberculosis confirmed by medical history or CT scan, active tuberculosis within 1 year before screening, or history of active tuberculosis \\> 1 year without standard treatment.\n* Active hepatitis: HBsAg positive with HBV DNA ≥ 2000 IU\u002FmL; HCV antibody positive with HCV viral load above the upper limit of normal.\n* Diagnosis of another malignancy within 5 years before the first dose, except malignancies with low risk of metastasis or death (5-year survival \\> 90%), such as adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* Administration of live attenuated vaccine within 4 weeks before the first dose. If enrolled, patients must not receive live vaccines during the study or within 120 days after the last dose of iparomlimab and tuvonralimab.\n* Known hypersensitivity or intolerance to any study drug(s) and\u002For their components.\n* Toxicity from prior anti-tumor therapy that has not resolved to NCI-CTCAE v5.0 grade 0 or 1, or to the level specified in the inclusion\u002Fexclusion criteria, except alopecia or pigmentation.\n* Pregnant or lactating female.\n* Participation in another clinical study, unless it is an observational, non-interventional study or the follow-up period of an interventional study.\n* Any other conditions judged by the investigator that may result in premature discontinuation from the study, including other severe diseases (including psychiatric disorders) requiring concurrent treatment, alcoholism, drug abuse, family or social factors that may affect patient safety or compliance.",{"count":369,"type":22},55,[371],"PHASE4","This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line treatment for unresectable locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.",[374,29,375],"Gastric Cancer (Diagnosis)","Gastroesophageal Junction Adenocarcinoma","2026-03-24",{"date":352,"type":42},{"date":303,"type":22},{"date":380,"type":22},"2029-06-30",{"name":382,"class":146},"Huazhong University of Science and Technology",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":399,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":4},"100627804","phase-1-qls5132-combination-therapy-in-advanced-solid-tumors-100627804","NCT07453394","QLS5132 Combination Therapy in Advanced Solid Tumors","A Phase Ib\u002FII Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenous QLS5132 Combination Therapy in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Advanced solid tumors;\n2. Measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1);\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n4. Adequate organ function;\n5. Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to National Cancer Institute-Common Terminology Criteria for Adverse Events \\[NCI-CTCAE\\] v5.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral.\n\nExclusion Criteria:\n\n1. Previous treatment with drugs targeting CLDN6 (including antibody-drug conjugates \\[ADCs\\]), or any drug containing topoisomerase I inhibitors (including ADCs);\n2. Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 2 weeks with small molecule and within 4 weeks with biologic before the first dose of QLS5132;\n3. Progressive or symptomatic brain metastases;\n4. Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection;\n5. History of significant cardiac disease, or poorly controlled diabetes mellitus;\n6. History of recurrent autoimmune diseases;\n7. History of myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML);\n8. History of a second primary malignancy;\n9. If female, is pregnant or breastfeeding;\n10. Be allergic to any component of QLS5132 or its excipients.",{"count":391,"type":22},626,[60,348],"The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced solid tumors. This is a multicenter, open-label study consisting of two parts: dose escalation and tumor-specific expansion.\n\nThe main questions it aims to answer are:\n\n* In the dose-escalation part: What is the safety, tolerability, PK profile, and preliminary efficacy of QLS5132 combination therapy, and what are the recommended dose(s) for expansion?\n* In the expansion part: What is the anti-tumor efficacy and further safety profile of QLS5132 combination therapy at the selected dose(s) in participants with specific tumor types?\n\nParticipants will:\n\n* Be enrolled in sequential cohorts to receive QLS5132 in combination with other anticancer agents.\n* Undergo regular assessments for safety, drug concentration levels (PK), and tumor response.",[29,395,396,397,398],"Non-small Cell Lung Cancer (NSCLC)","Endometrial Cancer","Advanced Solid Tumors","Ovarian Cancer",[400],"CLDN6 ADC","2026-03-04",{"date":403,"type":42},"2026-03-06",{"date":405,"type":22},"2026-04",{"date":407,"type":22},"2029-02",{"name":409,"class":49},"Qilu Pharmaceutical Co., Ltd.",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":85},"100622993","phase-1-a-study-of-sh009-injection-in-patients-with-advanced-solid-tumors-100622993","NCT07390838","A Study of SH009 Injection in Patients With Advanced Solid Tumors.","An Open, Multicenter, Phase I Clinical Study on the Safety, Efficacy, and Pharmacokinetics of SH009 Injection in Patients With Advanced Solid Tumors.","Inclusion Criteria:\n\n* (1) Age≥18 years old at the time of informed consent, male or female;\n* (2) Subjects with histologically confirmed locally advanced, recurrent, or metastatic solid tumors (including but not limited to colorectal cancer, gastric cancer, hepatocellular carcinoma, head and neck cancer, breast cancer, non-small cell lung cancer, esophageal cancer, etc.) who have experienced disease progression or intolerance to at least one prior line of systemic therapy, and for whom no acceptable standard therapy exists or who cannot benefit from or tolerate standard therapy;\n* (3) Subjects must have at least one measurable lesion per RECIST 1.1 criteria. A lesion that has been previously irradiated can only be considered measurable if there is documented progression at that site following radiotherapy;\n* (4) Archival tumor tissue samples are available, or the subject agrees to undergo a tumor biopsy for the determination of PD-L1 and CD47 expression levels and other biomarker analyses;\n* (5) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2;\n* (6) Life expectancy ≥12 weeks;\n* (7) Bone marrow function meets the following criteria: neutrophil count ≥ 1.5 × 10\\^9\u002FL; platelet count ≥ 90 × 10\\^9\u002FL (platelet count ≥ 75 × 10\\^9\u002FL in patients with liver cancer); hemoglobin (Hb) ≥ 90 g\u002FL;\n* (8) Liver function meets the following criteria: total bilirubin(TBIL) ≤ 1.5 × ULN (total bilirubin ≤ 3 × ULN for subjects with Gilbert's syndrome); aspartate aminotransferase (AST) and alanine and aminotransferase (ALT) ≤ 3 × ULN (ALT and AST ≤ 5 × ULN for subjects with liver cancer or liver metastases);\n* (9) Renal function meets the following criteria: serum creatinine clearance(CLcr) ≥ 50 mL\u002Fmin (calculated according to Cockcroft-Gault formula); urine dipstick test results show that urine protein \\\u003C 2 +, urine protein ≥ 2 + subjects should undergo 24-hour urine collection and urine protein content \\\u003C 1g within 24 hours;\n* (10) Coagulation function meets the following criteria: prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5× ULN;\n* (11) Female subjects of childbearing potential must use effective contraception during the trial and for 6 months after the last dose, and have a negative pregnancy test within 7 days before treatment initiation (except those who are surgically sterilized or postmenopausal). Male subjects must agree to use effective contraception during the trial and for 6 months after the last dose;\n* (12) The subject is fully informed about this trial before its commencement and voluntarily signs and dates the informed consent form.\n\nExclusion Criteria:\n\n* (1) Prior exposure to any CD47 antibody, SIRPα antibody, or CD47\u002FSIRPα recombinant protein;\n* (2) Prior treatment with adoptive cellular therapies such as CAR-T, TCR-T, or TIL. Prior administration of an anti-cancer vaccine, or use of live or live-attenuated vaccines within 4 weeks prior to the first dose;\n* (3) Systemic anti-tumor therapies within the specified timeframes prior to the first dose of study drug: Chemotherapy, antibody-based targeted therapy, endocrine therapy, or immunotherapy within 3 weeks. Mitomycin or nitrosoureas within 6 weeks. Oral fluoropyrimidines (e.g., S-1, capecitabine) and small molecule targeted agents within 2 weeks or 5 half-lives of the drug (whichever is longer).Chinese\u002Fherbal medicines with anti-cancer activity indicated in their labeling must be discontinued prior to enrollment. Prior radical radiotherapy within 3 months before study drug administration is excluded. Palliative radiotherapy administered within 2 weeks prior to dosing is allowed if the dose meets local palliative care standards and the radiation field covers less than 30% of the bone marrow area;\n* (4) Received any investigational drug within 28 days before administration of this trial, or participated in another clinical study at the same time, except for the following circumstances: the patient participated in an observational, non-interventional clinical study, or was in the follow-up period after the end of treatment in an interventional clinical study but the drug withdrawal had exceeded the washout period;\n* (5) Had major organ surgery (excluding puncture biopsy) or had significant trauma within 4 weeks before the first administration, or needed to undergo elective surgery during the trial period;\n* (6) Patients who received systemic glucocorticoids (dexamethasone \\> 10 mg\u002F day or equivalent dose of the same drug) or other immunosuppressive therapy within 14 days before the first administration; except for topical, ocular, intra-articular, intranasal, and inhaled glucocorticoids; short-term use of glucocorticoids for prophylactic treatment (e.g., prevention of contrast allergy);\n* (7) Symptomatic brain parenchymal or leptomeningeal metastases, deemed by the investigator as unsuitable for enrollment;\n* (8) Prior immunotherapy with ≥Grade 3 irAE or ≥Grade 2 immune-related myocarditis;\n* (9) Severe or uncontrolled systemic disease, including but not limited to: uncontrolled pleural or peritoneal effusion; uncontrolled diabetes; ventricular arrhythmia requiring intervention; acute coronary syndrome, congestive heart failure, stroke, or other ≥Grade 3 cardiovascular event within 6 months; NYHA Class ≥II or LVEF \\\u003C50%; clinically significant QTcF prolongation or arrhythmia risk (baseline QTcF \\>450 msec for males or \\>470 msec for females); clinically uncontrolled hypertension (SBP \\>160 mmHg and\u002For DBP \\>90 mmHg after treatment) as judged by the investigator. Subjects judged by the investigator as unsuitable due to any such condition;\n* (10) History of pneumonia requiring hormone therapy or interstitial lung disease (including past and current history); active pulmonary infection;\n* (11) Active infection requiring intravenous anti-infective therapy within 1 week prior to study drug administration (fever attributed to the tumor per investigator's judgment is acceptable). History of self-limited infections that have resolved is acceptable;\n* (12) Active Hepatitis B, Hepatitis C, or syphilis infection. Subjects positive for HBeAb or HBsAg are eligible if HBV-DNA ≤200 IU\u002FmL. Subjects positive for HCV-Ab are eligible if HCV-RNA ≤ the upper limit of normal at the research center. Subjects with hepatocellular carcinoma and HBV-DNA ≥2000 IU\u002FmL must receive antiviral\u002Fhepatoprotective therapy first and can only enroll after HBV-DNA decreases to \\\u003C2000 IU\u002FmL;\n* (13) History of primary immunodeficiency, including positive human immunodeficiency virus (HIV) test, or suffering from other acquired, congenital immunodeficiency diseases;\n* (14) History of other malignancies within 5 years prior to the first dose, except for:\n\n  a) Any other invasive malignancy, treated with curative intent, with a disease-free interval \\>3 years and deemed by the investigator not to affect efficacy evaluation for the current tumor. b) Adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or other locally cured cancers;\n* (15) History or presence of autoimmune disease within 2 years, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis or high risk (e.g., post-transplant immunosuppression). Exceptions: stable type 1 diabetes on fixed-dose insulin; autoimmune hypothyroidism on hormone replacement only; skin conditions not requiring systemic treatment (e.g., eczema, rash covering\\\u003C10% BSA, psoriasis without ocular symptoms);\n* (16) Arterial thromboembolic events within 6 months prior to the first dose, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. History of deep vein thrombosis, pulmonary embolism, or other serious thromboembolism within 3 months prior to the first dose (catheter-related or superficial venous thrombosis is not considered \"serious\"). Receiving thrombolytic or anticoagulant therapy for high thrombotic risk;\n* (17) Subjects who had receive allogeneic hematopoietic stem cell transplantation or solid organ transplantation (except corneal transplant);\n* (18) According to CTCAE 5.0, adverse reactions from previous anti-tumor therapy have not yet returned to ≤ grade 1 (except for toxicities which are judged by researchers to be safe, such as hair loss, pigmentation, hypothyroidism stabilized by hormone replacement therapy and peripheral neuropathy (need to recover to ≤ grade 2)). Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the study drug may be allowed after consultation with the medical monitor;\n* (19) Known history of severe hypersensitivity to macromolecular protein preparations\u002Fmonoclonal antibodies(CTCAE v5.0 Grade ≥3), or any component of the study drug;\n* (20) Known alcohol and\u002For drug dependence, or any other condition deemed by the investigator to affect the safety or compliance of the study treatment, including but not limited to psychiatric disorders;\n* (21) Pregnant or lactating women.",{"count":418,"type":22},150,[60],"Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors",[422,423,424,425,28,29,426],"Liver Cancer (Locally Advanced or Metastatic)","Lung Cancer (NSCLC)","Head and Neck Cancer Squamous Cell Carcinoma","Breast Cancer (Locally Advanced or Metastatic)","Solid Tumor Malignancies","2026-01-28",{"date":279,"type":42},{"date":430,"type":42},"2025-05-16",{"date":432,"type":22},"2028-12-30",{"name":434,"class":49},"Nanjing Sanhome Pharmaceutical, Co., Ltd.",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":442,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":85},"100620961","phase-1-to-evaluate-the-safety-and-tolerability-of-study-drug-as-a-third-line-and-beyond-therapy-for-recurrent-or-metastatic-gastric-cancer-100620961","NCT07364422","To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer","A Multicenter, Open-label, Single-arm, Dose-finding and Expansion Phase 1b\u002F2 Study to Evaluate the Safety and Tolerability of JPI-547 in Combination With Irinotecan as a Third Line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer","Inclusion Criteria:\n\n* Patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after second-line therapy.\n* Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Those with at least one measurable lesion in accordance with RECIST 1.1\n\nExclusion Criteria:\n\n* Patients with a confirmed specific medical history or past surgical history\n* Patients who meet specific criteria regarding prior treatment\n* Patients with a history of specific drug administration\n* Patients with specific comorbidities.\n* Patients who have undergone major surgery within 4 weeks prior to screening or are expected to require major surgery during the clinical trial are excluded. (However, those who have had minor surgeries\n* Patients with symptoms at the time of screening, who have not received treatment, or who have rapidly progressing central nervous system (CNS) metastases.\n* Patients with mental disorders or altered mental status\u002Fconsciousness (AMS) that impair their ability to understand this clinical trial for informed consent.\n* Pregnant or Lactating Women\n* Subjects with a history of severe allergic anaphylactic reactions to the investigational product and\u002For its components, or who have contraindications to the administration of the investigational product and\u002For irinotecan\n* Patients considered unsuitable for this clinical trial by the investigator.","19 Years",{"count":444,"type":22},49,[60,348],"This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer",[29],"2026-01-21",{"date":450,"type":42},"2026-01-23",{"date":452,"type":22},"2026-02-27",{"date":454,"type":22},"2029-02-28",{"name":456,"class":49},"Onconic Therapeutics Inc.",{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":185,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":482},"100621123","phase-3-adjuvant-oxaliplatin-plus-s-1-versus-docetaxel-plus-s-1-for-stage-iii-gastric-cancer-100621123","NCT07366528","Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer","Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer After D2 Gastrectomy (DRAGON-Adjuvant): a Multicenter, Open-label, Phase 3, Randomized, Non-inferiority Study","Inclusion Criteria:\n\n1. age 18 to 80 years old, male and female\n2. histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction\n3. patients underwent standard D2 gastrectomy and achieved R0 resection, and had no systemic therapy like neoadjuvant therapy\n4. American Joint Committee on Cancer stage IIIA (T2N3a, T3N2, T4aN1, T4aN2, T4bN0), IIIB (T1N3b, T2N3b, T3N3a, T4aN3a, T4bN1, T4bN2), IIIC (T3N3b, T4aN3b, T4bN3a, T4bN3b), and has Lauren classification\n5. with no evidence of metastatic disease\n6. ECOG 0 to 1\n7. Enough organ functions that can tolerate treatment: Absolute neutrophil count (ANC) ≥1.5x109\u002FL, White blood count ≥3.5x109\u002FL, Platelets ≥75x109\u002FL, Hemoglobin (Hb) ≥80g\u002FL, ALT\u002FAST ≤2.5x ULN (for patient with liver metastasis ALT\u002FAST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN.\n8. Woman of childbearing age should contracept for at least one month before screening and commit to using contraception throughout the entire study period and for the specified time after the study ends.\n9. Signed informed consent and willing to follow the study protocol\n\nExclusion Criteria:\n\n1. other primary malignancies, except for cured skin tumors or cervical carcinoma in situ\n2. severe complications that may lead to an expected survival time less than 5 years\n3. uncontrollable comorbidities, such as infectious disease, chronic diseases like hypertension, diabetes, heart diseases.\n4. allergic to study medication\n5. bowel obstruction or other conditions affecting oral administration\n6. organ functions that cannot tolerate study treatment\n7. other conditions that patients are unsuitable for this study assessed by the investigators",{"count":465,"type":22},387,[25],"This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.",[29,469,470,471,472],"Adjuvant Chemotherapy","Stage 3 Cancer","Docetaxel","Oxaliplatin","2026-01-16",{"date":475,"type":42},"2026-01-26",{"date":477,"type":42},"2025-12-15",{"date":479,"type":22},"2030-10-31",{"name":481,"class":146},"Ruijin Hospital",5,{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":185,"enrollmentInfo":491,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":492,"conditions":493,"keywords":497,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":85},"100617050","hyperthermic-intraperitoneal-chemoperfusion-hipec-in-gastric-cancer-100617050","NCT07313579","Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","Observational Prospective Cohort Study on Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","G-PEC","Inclusion Criteria:\n\n1. Age 18-80\n2. Hystologicaly proven gastric adenocarcinoma\n3. ECOG status 0-1\n4. Written consent to participate in the study\n5. Medically and technically operable gastric tumor\n6. Only T4a or T4b tumours with any peritoneal cytology status\n7. Cytologically positive peritoneal washings (cyt+) with any T and N criteria\n8. Adequate haemopoetic, renal and hepatic function (Hb \\> 120, PLT \\> 150\\*10\\^9\u002Fl, ALT \\\u003C 60, AST \\\u003C40, total bilirubin \\\u003C 21 µmol\u002Fl, Creatinine clearance (male - 90-140, female - 80-130 ml\u002Fmin)\n\nExclusion Criteria:\n\n1. Pregnancy\u002Fbreastfeeding\n2. ECOG status 2-4\n3. Concomitant malignancy\n4. Mitomycin and\u002For Cisplatin hypersensitivity\n5. Uncontrollable chronic diseases\n6. Patients with coexisting malignancy other than basal cell carcinoma of the skin within the last five years.\n7. Presence of metastases other than regional or peritoneal (such as liver, lungs, bone, brain, distant lymph nodes)\n8. History of allergic reactions associated with cisplatin and Mitomycin C\n9. Patients with psychiatric illness\u002Fsocial situations with impaired compliance\n10. •Refusal to participate",{"count":21,"type":22},"The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.",[29,494,495,496],"HIPEC","Peritoneal Metastases From Gastric Cancer","Hyperthermic Intraperitoneal Chemoperfusion",[192,494,496,498,499,500,501,502,503,504,505,506,507,508],"FLOT","Lymphadenectomy","Gastrointestinal Neoplasms","Digestive System Neoplasms","Gastrointestinal Diseases","Stomach Diseases","Stomach Neoplasms","Chemotherapy, Adjuvant","Combined Modality Therapy","Drug Therapy","Surgical Procedures","2026-01-10",{"date":511,"type":42},"2026-01-13",{"date":513,"type":42},"2025-12-01",{"date":515,"type":22},"2035-12-01",{"name":517,"class":146},"Ukrainian Society of Clinical Oncology",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":185,"enrollmentInfo":525,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":533,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":85},"100617225","phase-2-iparomlimab-and-tuvonralimab-ql1706-combined-with-chemotherapy-for-previously-untreated-advanced-or-metastatic-gastric-or-gastroesophageal-junction-cancer-100617225","NCT07315854","Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","A Prospective, Single-Center, Exploratory Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy in the Treatment of Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","Inclusion Criteria:\n\n* Voluntarily participate in the clinical study; fully understand and are informed about the study and sign the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures.\n* Age 18-80 years, gender is not limited.\n* Patients with locally advanced unresectable, recurrent unresectable, or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) confirmed by imaging and other examinations, and histopathologically confirmed as adenocarcinoma.\n* Provide a report confirming HER2 overexpression or amplification negativity; defined as IHC 0\u002F1+, or IHC 2+ with FISH\u002FISH negative.\n* No prior systemic therapy for advanced or metastatic GC\u002FGEJC (including anti-HER-2 therapy). Patients who have received adjuvant or neoadjuvant therapy (including chemotherapy, radiotherapy, or chemoradiotherapy) for GC\u002FGEJC are eligible if the time to first recurrence or disease progression is greater than 6 months from the end of the last treatment. Prior use of anti-tumor Traditional Chinese Medicine preparations is allowed but must be discontinued at least 2 weeks before enrollment.\n* ECOG performance status score of 0 or 1.\n* Must have at least one measurable lesion according to RECIST v1.1 definitions.\n* All acute toxicities caused by prior anti-tumor therapy or surgery must have resolved to Grade 0-1 (according to NCI CTCAE v5.0) or to the level specified in the inclusion\u002Fexclusion criteria. Alopecia, fatigue, and hearing loss, or other toxicities considered by the investigator not to pose a safety risk to the subject, are excluded.\n* Adequate organ function (laboratory tests within 7 days prior to treatment):\n\n  * Hematology (No blood transfusion, G-CSF use, or drug correction within 14 days prior to screening):\n  * White blood cell count (WBC) ≥ 3,000\u002Fmm³ (3.0 × 10⁹\u002FL);\n  * Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm³ (1.5 × 10⁹\u002FL);\n  * Platelet count (PLT) ≥ 100,000\u002Fmm³ (100 × 10⁹\u002FL);\n  * Hemoglobin (Hb) ≥ 9.0 g\u002FdL (90 g\u002FL).\n* Biochemistry (No albumin transfusion within 14 days prior to screening):\n\n  * Albumin ≥ 3.0 g\u002FdL (30 g\u002FL);\n  * Creatinine ≤ 1.5 × Upper Limit of Normal (ULN) or Creatinine Clearance ≥ 50 ml\u002Fmin (calculated using the Cockcroft-Gault formula);\n  * Total Bilirubin (BIL) ≤ 1.5 × ULN;\n  * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels ≤ 2.5 × ULN; for patients with liver metastases, ≤ 5 × ULN.\n* Coagulation: International Normalized Ratio (INR) ≤ 1.5, Prothrombin Time (PT), and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.\n* Urine: Urine protein \\\u003C 2+; if urine protein is ≥ 2+, 24-hour urine protein quantification must be ≤ 1g.\n* Life expectancy ≥ 3 months.\n* Women of childbearing potential must undergo a serum or urine pregnancy test within 7 days before starting treatment, with a negative result, and must not be lactating. All enrolled patients must use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n* Known squamous cell carcinoma, undifferentiated carcinoma, other histological types of gastric cancer, or mixed gastric cancer containing other histological types.\n* Active malignant tumors within the past 2 years, other than the tumor under study. Exceptions include subjects with locally curable cancers (that have been cured), such as basal or squamous cell skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix or breast.\n* Participation in a study of an investigational drug or receipt of investigational treatment or use of an investigational device within 4 weeks prior to the first dose.\n* Enrollment in another clinical study, unless it is an observational, non-interventional clinical study or the follow-up period of an interventional study (defined as \\>4 weeks since the last dose of the previous clinical study or \\>5 half-lives of the study drug).\n* Untreated Central Nervous System (CNS) metastases, or uncontrolled or symptomatic active CNS metastases. Patients with fully treated CNS metastases may be enrolled if neurological symptoms have returned to baseline levels at least 4 weeks prior to enrollment (excluding residual signs or symptoms related to CNS treatment). Additionally, subjects must have discontinued corticosteroids or be on a stable or tapering dose of prednisone ≤ 10 mg\u002Fd (or equivalent dose of other corticosteroids) for at least 4 weeks prior to enrollment.\n* Pleural effusion or ascites that remains uncontrolled despite puncture and drainage within 14 days prior to enrollment; symptomatic or moderate-to-large pericardial effusion.\n* Weight loss of more than 20% within 2 months prior to enrollment.\n* Received the following treatments or medications prior to enrollment:\n\n  * Major surgery within 28 days prior to enrollment (tissue biopsy for diagnosis and PICC\u002Fport implantation are allowed).\n  * Use of immunosuppressive drugs within 14 days prior to enrollment, excluding nasal\u002Finhaled corticosteroids or physiological doses of systemic steroids (i.e., ≤ 10 mg\u002Fd prednisone or equivalent).\n  * Vaccination with live attenuated vaccines within 28 days prior to enrollment or planned during the study period and within 60 days after the end of study drug treatment.\n  * Local anti-tumor therapy (e.g., radiotherapy or tumor embolization) within 28 days prior to enrollment.\n* Diagnosed with any other malignant tumor within 5 years prior to entering the study, except for cured cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma amenable to local treatment.\n* Presence of any active, known, or suspected autoimmune disease. Subjects in a stable state not requiring systemic immunosuppressive therapy are allowed, such as Type I diabetes, hypothyroidism requiring only hormone replacement therapy, and skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia).\n* Prior treatment with any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.\n* Significant clinical bleeding symptoms or definite bleeding tendency within 3 months prior to enrollment; gastrointestinal perforation and\u002For fistula within 6 months prior to enrollment; arterial\u002Fvenous thromboembolic events within 6 months prior to enrollment, such as cerebrovascular accident (including TIA, cerebral infarction), deep vein thrombosis, and pulmonary embolism (except for those with gastric cancer bleeding\u002Fperforation where symptoms disappeared after surgical resection).\n* Major vascular disease within 6 months before the start of study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis).\n* Severe, unhealed, or dehisced wounds, active ulcers, or untreated fractures.\n* Presence of \\> Grade 1 peripheral neuropathy.\n* History of intestinal obstruction and\u002For clinical signs or symptoms of gastrointestinal obstruction within 6 months before starting study treatment, including incomplete obstruction related to the underlying disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding. Patients with incomplete obstruction\u002Fobstruction syndrome at initial diagnosis who have symptom relief after definitive (surgical) treatment may be enrolled.\n* Interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, acute pneumonia, etc.).\n* Known history of active tuberculosis.\n* Known allergy to the study drug or any of its excipients; or history of severe allergic reactions to other monoclonal antibodies.\n* HIV infection or known Acquired Immunodeficiency Syndrome (AIDS); untreated active hepatitis (Hepatitis B defined as HBV-DNA ≥ 500 IU\u002Fml; Hepatitis C defined as anti-HCV positive and HCV RNA above the lower limit of detection) or co-infection with Hepatitis B and C.\n* Poorly controlled clinical cardiac symptoms or diseases, such as: (1) NYHA Class II or higher cardiac insufficiency or LVEF \\\u003C 50% on echocardiography; (2) Severe\u002Funstable angina; (3) Myocardial infarction within 12 months prior to enrollment; (4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; (5) Symptomatic congestive heart failure; (6) QTc \\> 480 ms.\n* Systemic use of antibiotics ≥ 7 days within 4 weeks prior to enrollment, or unexplained fever \\> 38.5°C during screening\u002Fbefore first dose (fever due to tumor causes is allowed per investigator judgment).\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Participation in any other drug clinical study within 4 weeks or 5 half-lives prior to enrollment.\n* Known history of psychotropic drug abuse or drug addiction.\n* Presence of other severe physical or mental illnesses or laboratory abnormalities that may increase the risk of participation, interfere with study results, or render the patient unsuitable for the study in the opinion of the investigator.",{"count":526,"type":22},32,[348],"The goal of this Phase II clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) combined with SOX chemotherapy (S-1 plus Oxaliplatin) in patients with previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer.\n\nThe main questions it aims to answer are:\n\n1、What is the objective response rate (ORR) of the combination of QL1706 and SOX chemotherapy? 2、What are the safety and tolerability of this combination therapy? Participants will：\n\n1. Receive Iparomlimab and Tuvonralimab (QL1706) via intravenous infusion every 3 weeks.\n2. Receive SOX chemotherapy (Oxaliplatin via intravenous infusion on Day 1 and S-1 orally twice daily for 14 days) every 3 weeks for up to 6 cycles.\n3. Continue maintenance therapy with QL1706 combined with S-1 after 6 cycles until disease progression or unacceptable toxicity.\n4. Undergo tumor imaging assessments (CT or MRI) every 6 weeks for the first 24 weeks, and then every 9 weeks thereafter to monitor the disease.",[29,530,531,532],"Gastroesophageal Junction Cancer","Advanced Gastric Cancer","Metastatic Gastric Cancer",[534,535,536,537,194,538,539],"Iparomlimab and Tuvonralimab","QL1706","Advanced or Metastatic Gastric Cancer","PD-1\u002FCTLA-4 Bispecific Antibody","Chemotherapy Combination","Gastric Cancer","2026-01-02",{"date":542,"type":42},"2026-01-06",{"date":544,"type":42},"2025-11-04",{"date":546,"type":22},"2029-12-31",{"name":548,"class":146},"Beijing Friendship Hospital",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":154,"sex":18,"minAge":155,"maxAge":209,"enrollmentInfo":555,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":565,"leadSponsor":567,"locationsCount":4},"100618475","the-application-of-extracellular-vesicle-detection-in-gastric-juice-based-on-metamaterial-sensing-in-the-diagnosis-of-gastric-cancer-and-related-diseases-100618475","NCT07332104","The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Gastric Cancer and Related Diseases","Inclusion Criteria:\n\n* Patients underwent gastroscopy and treatment at the Endoscopy Center of Beijing Friendship Hospital, Capital Medical University, and received pathological biopsy.\n* Previous gastroscopy suggested the possibility of lesions.\n* No previous history of gastrointestinal cancer.\n\nExclusion Criteria:\n\n* Patients could not cooperate with the examination or had contraindications to endoscopy.\n* Previous history of gastrointestinal tumors, gastrointestinal surgery, physical and chemical injuries of the gastrointestinal tract.\n* Severe bile reflux.\n* Take simethicone and other defoaming agents before examination.\n* Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.",{"count":556,"type":22},100,"After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. The medical history and treatment records and gastric fluid samples were analyzed.",[29,374],[192,560],"Extracellular vesicles","2025-12-28",{"date":563,"type":42},"2026-01-12",{"date":477,"type":22},{"date":566,"type":22},"2026-12-15",{"name":548,"class":146},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":129,"enrollmentInfo":575,"targetDuration":4,"studyType":23,"phases":577,"briefSummary":578,"conditions":579,"keywords":580,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":85},"100618425","phase-3-robotic-vs-laparoscopic-gastrectomy-for-ct4a-gastric-cancer-100618425","NCT07331454","Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer","Robot-Assisted Versus Laparoscopy-Assisted Gastrectomy in Patients With cT4a Gastric Cancer: A Multicenter, Randomized Controlled, Phase III Study","Inclusion Criteria:\n\nHistologically confirmed gastric or Siewert type III (and selected type II) gastro-oesophageal junction adenocarcinoma, clinical stage cT4a without bulky lymph-node enlargement on contrast-enhanced CT or MRI No prior neoadjuvant chemotherapy, radiotherapy, or other anti-cancer therapy Tumour deemed amenable to R0 resection by a board-certified gastric surgeon and radiologist ECOG performance status 0-1 Estimated life expectancy ≥ 6 months\n\nAdequate organ function defined by:\n\n* ANC ≥ 1.2 × 10⁹\u002FL, platelet ≥ 100 × 10⁹\u002FL, Hb \\> 8 g\u002FdL (no transfusion\u002FG-CSF within 14 days)\n* ALT\u002FAST ≤ 2.5 × ULN, total bilirubin ≤ 1.5 × ULN (or isolated indirect hyperbilirubinaemia)\n* Serum creatinine ≤ 1.5 × ULN and calculated creatinine clearance ≥ 60 mL\u002Fmin\n* INR or PT ≤ 1.5 × ULN (therapeutic low-dose anticoagulation allowed)\n* TSH and free T4 within normal limits or clinically insignificant deviation BMI ≥ 18.5 kg\u002Fm² or body weight ≥ 40 kg Signed informed consent\n\nExclusion Criteria:\n\ncT4b disease, distant metastasis, or peritoneal cytology positive for malignancy Bulky lymph-node conglomerates (\\> 3 cm short axis) or N3 disease precluding D2 dissection Previous gastrectomy or major upper-abdominal surgery (except uncomplicated laparoscopic cholecystectomy) within 5 years Concurrent malignancy within 5 years (except adequately treated basal-cell carcinoma, carcinoma in situ, or stage I tumours) Gastric cancer arising from emergency presentation (bleeding, perforation, obstruction) Planned multi-visceral resection for non-oncologic indication Active bleeding diathesis; INR \\> 1.5 off anticoagulants; history of grade ≥ 3 bleeding within 4 weeks Arterial or venous thrombo-embolic event within 6 months Clinically significant cardiovascular disease: NYHA class III-IV heart failure, LVEF \\\u003C 50 %, myocardial infarction or unstable arrhythmia within 6 months, QTc ≥ 450 ms (men) or ≥ 470 ms (women) Severe chronic pulmonary disease: FEV₁ \\\u003C 50 % predicted or oxygen-dependent Uncontrolled diabetes (HbA1c \\> 8 %), active autoimmune disease requiring systemic immunosuppression, or corticosteroids \\> 10 mg\u002Fday prednisone equivalent within 14 days Active infection requiring systemic antibiotics, HIV, hepatitis B (HBV DNA ≥ 500 copies\u002FmL), hepatitis C, or tuberculosis Pregnancy, lactation, or fertile participants unwilling to use effective contraception Psychological disorder, substance abuse, or any condition that, in the investigator's opinion, would compromise protocol compliance or safety",{"count":576,"type":22},335,[25],"The goal of this multicenter, randomized, phase III clinical trial is to test whether robot-assisted radical gastrectomy improves 3-year recurrence-free survival versus laparoscopy-assisted radical gastrectomy in adults aged 18-80 years with previously untreated, resectable cT4a gastric adenocarcinoma and non-bulky lymph nodes; the main questions are whether the robotic approach confers superior RFS and maintains equivalent peri-operative safety (Clavien-Dindo ≥ II complications) and better secondary oncologic outcomes, and participants will be randomized 1:1 to undergo standardized D2 resection via robotic or laparoscopic technique and followed for 5 years with scheduled recurrence, survival, and quality-of-life assessments.",[29],[581,582,583],"gastric cancer","robotic gastrectomy","laparoscopic gastrectomy",{"date":563,"type":42},{"date":586,"type":22},"2026-02-01",{"date":588,"type":22},"2031-12-31",{"name":590,"class":146},"The First Affiliated Hospital with Nanjing Medical University",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":23,"phases":601,"briefSummary":602,"conditions":603,"keywords":604,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":85},"100616884","phase-2-shr-1701--rivoceranib--shr-2554-in-advanced-gc-after-first-line-immunotherapy-failure-100616884","NCT07311408","SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure","SHR-1701 Combined With Rivoceranib, With or Without SHR-2554, in Patients With Advanced Gastric Cancer Who Have Failed First-Line Immunotherapy","SHR-2554","Inclusion Criteria:\n\n1. Age ≥ 18 years, male or female.\n2. Histologically or pathologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.\n3. Disease progression on or intolerance to a prior treatment regimen that contained an immune checkpoint inhibitor (ICI).\n4. HER2-negative expression.\n5. Willingness to provide tumor tissue samples from prior to the first systemic therapy for biomarker analysis (e.g., PD-L1). Freshly obtained biopsies are preferred; if unavailable, archived formalin-fixed paraffin-embedded (FFPE) tissue blocks or 5-8 slides of 3-5μm thickness are acceptable.\n6. At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n8. Life expectancy ≥ 12 weeks.\n9. Adequate organ and bone marrow function, defined as:\n\n   1. Hemoglobin ≥ 90 g\u002FL (no blood transfusion within 14 days);\n   2. Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL;\n   3. Platelet count ≥ 90 × 10\\^9\u002FL;\n   4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN);\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN;\n   6. Serum creatinine ≤ 1.5 × ULN;\n   7. Left ventricular ejection fraction (LVEF) ≥ 50%; QTc interval \\\u003C 450 ms for males and \\\u003C 470 ms for females.\n10. For patients not on therapeutic anticoagulation: International Normalized Ratio (INR) ≤ 1.5 and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN. Patients receiving full-dose or parenteral anticoagulants are eligible provided the dose has been stable for at least 2 weeks prior to study entry and relevant coagulation parameters are within the therapeutic range.\n11. For women of childbearing potential: a negative serum or urine pregnancy test within 14 days prior to enrollment, and agreement to use highly effective contraception during the study and for 3 months after the last dose of the study drug. For male patients: surgical sterilization or agreement to use highly effective contraception during the study and for 3 months after the last dose.\n12. Recovery from toxicities of prior therapies to ≤ Grade 1 (per NCI CTCAE). For prior surgeries, the wound must have healed completely.\n13. Voluntary participation, provision of signed informed consent, expected good compliance, and ability to comply with the study protocol requirements.\n\nExclusion Criteria:\n\n1. Gastrointestinal perforation and\u002For fistula within 6 months prior to treatment, or active gastrointestinal bleeding within 3 months.\n2. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.\n3. Known history of allergy to any component of the investigational drugs or their excipients.\n4. Prior treatments as follows:\n\n   1. Treatment with any other investigational agent within 4 weeks prior to the first dose of the study drug, or within 5 half-lives of the previous investigational agent (whichever is longer).\n   2. Concurrent enrollment in another interventional clinical study. (Observation studies or follow-up phases of interventional studies are permitted).\n   3. Any antitumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biotherapy, or tumor embolization) within 2 weeks prior to the first dose of the study drug.\n   4. Requirement for systemic corticosteroids (\\>10 mg prednisone equivalent daily) within 2 weeks prior to the first dose. The use of corticosteroids for premedication with certain chemotherapy regimens, inhaled or topical steroids, and adrenal replacement therapy at doses ≤10 mg\u002Fday prednisone equivalent is permitted. Other cases require discussion with the Investigator.\n   5. Prior administration of an anti-tumor vaccine or live vaccine within 4 weeks prior to the first dose.\n   6. Major surgery or significant trauma within 4 weeks prior to the first dose.\n5. History of leptomeningeal metastasis, or current evidence of leptomeningeal metastasis or active brain metastases. (Patients with stable, treated brain metastases may be discussed for eligibility).\n6. Active autoimmune disease or history of autoimmune disease requiring systemic treatment in the past 2 years. Exceptions include vitiligo, resolved childhood asthma\u002Fatopy, hypothyroidism stable on hormone replacement, or Type I diabetes stable on insulin regimen.\n7. Immunodeficiency history, including positive HIV test, other acquired\u002Fcongenital immunodeficiency disorders, history of organ transplant or allogeneic bone marrow transplantation, or active hepatitis.\n8. Poorly controlled cardiovascular diseases, including but not limited to: (1) Heart failure of NYHA Class II or higher; (2) Unstable angina; (3) Myocardial infarction within the past year; (4) Clinically significant supraventricular or ventricular arrhythmia without effective medical control.\n9. Severe infection within 4 weeks prior to the first dose. Active pulmonary inflammation on baseline imaging, or signs\u002Fsymptoms of active infection within 2 weeks prior to the first dose.\n10. History of interstitial lung disease.\n11. Active tuberculosis infection based on history\u002FCT findings, or history of active TB within one year prior to enrollment, or prior active TB over one year ago without appropriate treatment.\n12. Diagnosis of another malignancy within 5 years prior to the first dose. Exceptions include malignancies with low risk of metastasis\u002Fdeath.\n13. Pregnancy or lactation.\n14. Any other condition deemed by the investigator to potentially compromise patient safety or study compliance. -",{"count":600,"type":22},40,[348],"To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment",[29,375],[539,375,605,606],"Rivoceranib","Failed First-Line Immunotherapy","2025-12-25",{"date":609,"type":42},"2025-12-31",{"date":611,"type":22},"2026-01-01",{"date":613,"type":22},"2029-12-01",{"name":615,"class":146},"Jingdong Zhang",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":154,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":625,"conditions":626,"keywords":630,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":85},"100610220","a-noninvasive-and-screening-mirna-signature-for-gastrointestinal-cancer-100610220","NCT07224750","A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer","MiGIC","Inclusion Criteria:\n\n1. Adults aged 18 years or older at the time of blood sample collection.\n2. Patients with a confirmed diagnosis of one of the following gastrointestinal cancers: Hepatocellular carcinoma (HCC), Cholangiocarcinoma (CCA), Pancreatic ductal adenocarcinoma (PDAC), Esophageal squamous cell carcinoma (ESCC), Gastric cancer (GC), Colorectal cancer (CRC), Non-cancer control participants, including healthy volunteers or patients with benign gastrointestinal conditions.\n3. Availability of retrospective blood samples collected according to institutional protocols.\n4. Willingness to allow use of de-identified clinical and demographic data for research purposes.\n\nExclusion Criteria:\n\n* other active malignancies; insufficient sample quality\u002Fvolume; recent chemotherapy\u002Fradiotherapy\u002Fsurgery; any condition preventing reliable participation.",{"count":624,"type":22},1000,"Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive, or insufficiently sensitive for detecting early-stage disease, and are therefore not suitable for population-wide screening or for simultaneously identifying multiple GI tumor types. As a result, many patients are diagnosed at advanced stages, when therapeutic options are limited and prognosis is poor.\n\nCirculating microRNAs (miRNAs) offer a promising alternative, as they are stable in peripheral blood and reflect tumor-related molecular alterations. In this study, the investigators aim to develop and validate a robust, noninvasive miRNA-based signature capable of distinguishing GI cancers from non-malignant controls. By integrating multi-cohort datasets and applying machine learning-based feature selection and predictive modeling, the investigators will construct a screening panel optimized for reproducibility, scalability, and early-stage detection. This noninvasive miRNA signature has the potential to support accessible, cost-effective, and clinically practical population-level screening for GI cancers, ultimately facilitating earlier diagnosis and improving outcomes for participants.",[217,627,216,628,29,629],"Cholangiocarcinoma","Esophageal Squamous Cell Carcinoma (ESCC)","Colorectal Cancer Screening",[631,632,633,634,635],"Noninvasive screening","Circulating miRNA","Machine learning","Gastrointestinal cancer","Blood-based cancer detection","2025-11-24",{"date":638,"type":42},"2025-11-26",{"date":640,"type":42},"2024-06-21",{"date":642,"type":22},"2026-06-18",{"name":644,"class":146},"City of Hope Medical Center",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":4,"eligibilityCriteria":651,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":652,"targetDuration":4,"studyType":23,"phases":653,"briefSummary":654,"conditions":655,"keywords":659,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":675},"100533194","ppg-vs-icg-in-gastrointestinal-resections-100533194","NCT06222645","PPG vs. ICG in Gastrointestinal Resections","Comparison Between Fluorescenceimaging With Photoplethysmography （PPG） and Indocyaningreen (ICG) for Tissue Perfusion in Gastrointestinal Resections","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years).\n* Scheduled to undergo an elective gastrointestinal resection requiring a primary gastro-intestinal or entero-enteric anastomosis.\n* Able to understand and provide written informed consent.\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to indocyanine green (ICG), iodine, or any component of the ICG formulation.\n* Severe hepatic impairment (e.g., Child-Pugh Class C).\n* Pregnancy or lactation.\n* Emergency surgery.\n* Inability to comply with the study protocol or follow-up schedule in the investigator's judgment.",{"count":21,"type":22},[133],"This randomized controlled trial compares a novel optical technique against the standard of care for assessing tissue perfusion in gastrointestinal surgery. Participants are randomized to receive either intraoperative imaging photoplethysmography (iPPG) or indocyanine green (ICG) fluorescence imaging. In the ICG group, the fluorescence data are comprehensively analyzed in two distinct ways: (1) Qualitative Assessment: real-time visual interpretation of the angiogram flow by the operating surgeon; and (2) Quantitative Assessment: software-based analysis of fluorescence kinetics (e.g., time-to-peak, maximum intensity) to generate objective perfusion parameters. The study aims to determine the agreement between the iPPG-based evaluations and both the qualitative and quantitative dimensions of the ICG standard.",[656,657,658,500,29,298],"Anastomosis","Perfusion","Postoperative Complications",[660,661,662,663,664,665,666],"Photoplethysmography","Indocyanine Green","Fluorescence Imaging","Anastomotic Leak","Gastrointestinal Surgery","Tissue Perfusion","Intraoperative Monitoring",{"date":668,"type":42},"2025-11-18",{"date":670,"type":42},"2023-11-01",{"date":672,"type":22},"2026-05-31",{"name":674,"class":146},"Saint Petersburg State University, Russia",3,{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":682,"eligibilityCriteria":683,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":185,"enrollmentInfo":684,"targetDuration":685,"studyType":159,"phases":4,"briefSummary":686,"conditions":687,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":695,"locationsCount":85},"100607022","the-possible-range-of-no4sb-lymph-node-dissection-of-locally-advanced-distal-gastric-cancer-100607022","NCT07183150","The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer","A Single Center, Prospective Study on the Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer","Range of 4sb","Inclusion Criteria:\n\n* 18 and ≤ 75 years of age; Preoperative gastric cancer patients with pathologically confirmed; Had been treated with Radical resection (D2, R0) of gastric cancer (Lymph node≥16); Willing and able to comply with the program during the study period; Physical condition and organ function allows to tolerable abdominal surgery; Written informed consent provided; Under radical laparoscopic distal subtotal gastrectomy With more than a 6-month life expectancy; No other serious concomitant diseases; Sufficient organ functions; No previous history of chemotherapy or radiotherapy; Clinical stage: T2-4aNxM0; Karnofsky performance status (KPS)\\>60; Eastern Cooperative Oncology Group Performance Status (ECOG): 0-1.\n\nExclusion Criteria:\n\nPregnancy or breast feeding; Patients with Serious liver disease (such as cirrhosis, etc.), kidney disease, respiratory disease or uncontrolled diabetes, hypertension and other chronic systemic diseases, heart disease with Clinical symptoms, such as congestive heart failure, coronary heart disease symptoms, drug is difficult to control arrhythmia, hypertension, or six months had a myocardial infarction attack, or cardiac insufficiency; Organ transplantation patients need immunosuppressive therapy; Severe recurrent infections were not controlled or with other serious concomitant diseases; Patients got other primary malignant tumors (except curable skin basal cell carcinoma and cervical cancer in situ) except gastric cancer within 5 years; Psychiatric disease which require treatment; Have the history of organ transplantation; Within 6 months before study starts and in the process of this study, patients participate in other clinical researches.",{"count":316,"type":22},"3 Years","The main purpose of this study is to evaluate the reasonable range of No.4sb lymph node dissection of locally advanced distal gastric cancer.",[29,688],"No.4sb","2025-09-14",{"date":691,"type":42},"2025-09-19",{"date":693,"type":42},"2025-08-18",{"date":281,"type":22},{"name":696,"class":146},"Tianjin Medical University Cancer Institute and Hospital"]